Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)Adi Diab, Daniel C. Cho, Nizar M. Tannir et al.|Cancer Discovery|2020Cited by 239
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid TumorsSalah-Eddine Bentebibel, Adi Diab, Mario Sznol et al.|Cancer Discovery|2019Cited by 233
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapyMeenu Sharma, Willem W. Overwijk, Hiep Khong et al.|Nature Communications|2020Cited by 172
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapyDeborah H. Charych, Jonathan Zalevsky, Samira Khalili et al.|PLoS ONE|2017Cited by 145
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic MelanomaAdi Diab, Michael E. Hurwitz, Scott S. Tykodi et al.|Journal of Clinical Oncology|2021Cited by 81